GlassScriptPrepare for your visit
David J Mooney
Hematology & Oncology · Birmingham, AL · NPI 1831350198
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$120,228.11
in general payments reported to CMS, 2019-2025 · $46K in 2025
The $46K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Who reported paying
General payments only, top 6 by amount.
- Onmark, INC. $86,510.03
- Novartis Pharmaceuticals Corporation $2,746.08
- Genentech USA, INC. $2,628.21
- E.R. Squibb & Sons, L.L.C. $2,047.82
- Pfizer INC. $2,003.08
- Mckesson Specialty Care Distribution, LLC $1,410.07
Drugs and devices associated with these payments
Lenvima Opdivo Reblozyl Xtandi Kisqali Jaypirca Ultomiris Enhertu Darzalex Fabhalta Orserdu Verzenio
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw David Mooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/1212878/david-j-mooney